Next Steps in the Development of Axatilimab
Corey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.
Video content above is prompted by the following questions:
- While axatilimab targets a novel pathway in cGVHD, what other unmet needs persist in managing this condition?
- What are the key challenges in improving overall outcomes and quality of life for patients with cGVHD?
- Are there any promising emerging therapies, combination approaches, or ongoing trials that could complement axatilimab's role in the cGVHD treatment landscape?
- Are there any promising emerging therapies, combination approaches, or ongoing trials that could complement axatilimab's role in the cGVHD treatment landscape?
- What are the key challenges in improving overall outcomes and quality of life for patients with cGVHD?
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
October 23rd 2024During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
